Pliant Therapeutics, Inc. (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company developing integrin-based therapies, not an exchange-traded fund. Three recent, individually attributable analyst price targets were reviewed: Canaccord Genuity (Edward Nash) at $3.00 with a Hold, Piper Sandler (Yasmeen Rahimi) at $3.00 with an Overweight, and RBC Capital (Brian Abrahams) at $2.00 with a Hold, all set in March 2026. The arithmetic mean of these three is about $2.67, which I round to a clean central target of $2.50; the range is $2.00 to $3.00. Aggregators such as TipRanks and MarketWatch report a similar picture of roughly five covering analysts within a $2.00–$3.00 band and an average near $2.50–$2.67.
The dispersion is modest in dollar terms but reflects genuine disagreement about the probability-weighted value of a single pipeline asset. Bullish and neutral analysts anchor on the potential of PLN-101095, while cautious analysts point to a long wait for pivotal data. Notably, J.P. Morgan downgraded the shares to Underweight in October 2025, and Piper Sandler and Canaccord both cut targets from $4.00 to $3.00 in March 2026, underscoring how the company's pivot away from fibrosis has reset expectations.
Shares last traded near $0.86, giving the stock a market capitalization of roughly $53 million even though the company reported about $172 million in cash and short-term investments as of mid-2026. Reaching $2.50 would require a gain of approximately 190% — by any standard, a very large move. The implied path is not gradual earnings growth but binary, event-driven re-rating: investors would need to believe the oncology program has meaningful, approvable potential.
Pliant is now essentially a one-drug story. PLN-101095, an oral dual-selective inhibitor of the αvβ8 and αvβ1 integrins, is being tested with Merck's pembrolizumab (Keytruda) in patients with checkpoint-inhibitor-refractory solid tumors. Early Phase 1 data reported responses in a small, heavily pretreated group, and the FDA granted Fast Track designation. However, the confirmatory FORTIFY Phase 1b trial is still enrolling, with interim data not expected until 2027.
PLRX is in a pronounced long-term downtrend, down roughly 52% over the past year and near 96% since its 2020 IPO. The 52-week range spans approximately $0.83 to $1.95, and the stock has been trading below both its 50-day and 200-day moving averages. The $0.83 area represents a key support level — the recent 52-week low — while $1.00 acts as a psychological round-number resistance level. A sustained move above $1.00 would be an important first structural step on any path toward the $2.50 target.
Analyst price targets typically reflect a research horizon of roughly 12 months, though for a clinical-stage company the actual catalyst timeline matters more than the calendar. Meaningful data from FORTIFY is not expected until 2027, which means near-term price action may depend on enrollment updates, third-quarter 2026 earnings, changes in cash guidance, and any regulatory or partnership developments. Investors should watch analyst revisions, enrollment progress for PLN-101095, and whether the company discloses any advancement of its integrin-targeted delivery platform.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile micro-cap like Pliant Therapeutics, such tools can help traders discover emerging opportunities, keep tabs on existing positions, and spot shifting trends more efficiently than manual screening. Traders exploring this space can use the signals to complement their own research and stay alert to momentum changes across the broader market.
The $2.50 central target — derived from three attributable analyst targets averaging about $2.67 — would require PLRX to gain roughly 190% from its current level near $0.86. That is a very large move for a company whose fortunes now rest on a single early-stage oncology asset with no efficacy readout expected until 2027. The bull case leans on encouraging early data, Fast Track designation, a strong cash runway, and a negative enterprise value, while the bear case emphasizes the small dataset, the lengthy catalyst gap, persistent losses, and a sub-$1 share price near historic lows. Reaching the target is possible but contingent on clinical and regulatory outcomes that remain years away; the near-term balance of evidence points to continued volatility rather than any near-term re-rating.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, PLRX has been loosely correlated with SION. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if PLRX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To PLRX | 1D Price Change % | ||
|---|---|---|---|---|
| PLRX | 100% | -1.74% | ||
| SION - PLRX | 43% Loosely correlated | +3.64% | ||
| RXRX - PLRX | 37% Loosely correlated | -6.70% | ||
| EDIT - PLRX | 36% Loosely correlated | -8.91% | ||
| AXSM - PLRX | 35% Loosely correlated | +5.23% | ||
| BCYC - PLRX | 35% Loosely correlated | -2.12% | ||
More | ||||